ArticleBMC psychiatry2022
Economic burden of major depressive disorder: a case study in Southern Iran.
Article in BMC psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effects of Physical Exercise on Executive Function in Adults with Depression: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2022Pooled it
- The Efficacy of Omega-3 Fatty Acids as the Monotherapy for Depression: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.Nutrients · 2024Trial
- Integrated Bulk and Single-Cell Transcriptomic Analysis Followed by Clinical Validation Reveal Programmed Cell Death-Related Shared Molecular Signatures in OA and MDD.International journal of molecular sciences · 2026Article
- Economic burden of knee replacement, a case of Bushehr, Iran in 2023-2024.Cost effectiveness and resource allocation : C/E · 2026Article
- Quality of Service and Cost of Managing an Episode of Major Depressive Disorder: A Cohort Study in Iran.Archives of Iranian medicine · 2026Article
- Mental Health and Mental Health Care in Iran: Addressing Social Inequalities.Healthcare (Basel, Switzerland) · 2025Review
- The Art of Nanoimmunobiotechnomedicine in Depression Management.Advanced pharmaceutical bulletin · 2025Review
- Genetic Insights Into Skin Diseases and Depression: Evidence From East Asian Mendelian Randomization Analysis.Alpha psychiatry · 2025Article
- The Impact of Anhedonia on the Disease Burden of Major Depressive Disorder in the Asia-Pacific Region: A Cross-Sectional Real-World Study.Neuropsychopharmacology reports · 2025Article
- Enhancing Transcriptomic Insights into Neurological Disorders Through the Comparative Analysis of Shapley Values.Current issues in molecular biology · 2024Article
- Associations between dairy and alcohol consumption and major depressive disorder in a mendelian randomization study.Scientific reports · 2024Article
- The economic burden of bipolar disorder: a case study in Southern Iran.Cost effectiveness and resource allocation : C/E · 2024Article
- Preexisting depression and COVID-19: a cohort study on the risk of susceptibility and hospitalization.BMC psychiatry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDepression disorders are a leading cause of disability in the world which imposes a significant economic burden on patients and societies The present study aimed to determine the economic burden of Major Depressive Disorder (MDD) on the patients referred to the reference psychiatric single-specialty hospitals in southern Iran in 2020.
methodsThis cross-sectional research is a partial economic evaluation and a cost-of-illness study conducted in southern Iran in 2020. A total of 563 patients were enrolled through the census method, and a researcher-made data collection form was used to gather the required information. The prevalence-based and the bottom-up approaches were also used to collect the cost information and calculate the costs, respectively. The data on direct medical, direct non-medical, and indirect costs were obtained using the information in the patients' medical records and insurance bills as well as their self-reports or those of their companions. To calculate the indirect costs, the human capital approach was used as well.
resultsThe results showed that the annual cost of MDD was $ 2717.41 Purchasing Power Parity (PPP) (USD 2026.13) per patient in 2020. Direct medical costs accounted for the largest share of the costs (73.68%), of which hoteling and regular beds expenses were the highest (57.70% of the total direct medical costs). The shares of direct non-medical and indirect costs were 7.52 and 18.80%, respectively, and the economic burden of the disease in the country was estimated at $7,120,456,596 PPP (USD 5,309,088,699).
conclusionIn general, due to the high prevalence of MDD and the chronicity of the disease, the costs of its treatment can impose a heavy economic burden on the society, healthcare system, insurance system, and the patients themselves. Therefore, it is suggested that health policymakers and managers should take appropriate measures to increase the basic and supplemental insurance coverage of these patients. In addition, in order to reduce the costs, proper and equitable distribution of psychiatrists and psychiatric beds, expansion of home care services, and use of Internet-based technologies and the cyberspace to follow up the treatment of these patients are recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.